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Summary
OBJECTIVES: To report survival following different opera-
tive strategies and perioperative chemotherapy in patients
with synchronous colorectal liver metastases in a tertiary
academic referral centre.
METHODS: We performed a retrospective analysis,
based on a prospective database, of patients who pre-
sented with synchronous colorectal liver metastases. Fol-
low-up data were obtained from medical records, letters
or telephone contacts. The main endpoint was overall sur-
vival. An additional event of interest was postoperative
mortality according to treatment strategy. Predefined vari-
ables were analysed to identify associated risk factors.
RESULTS: Overall, 109 patients undergoing liver resec-
tion for synchronous colorectal liver metastases between
2000 and 2010 were identified. The majority of patients
had resection of the primary tumour first (n = 82), the
classic approach; notably fewer were treated according
to a combined (n = 20) or a reverse “liver first” strategy
(n = 7). Most patients (92%) received preoperative, in-
terval and/or postoperative chemotherapy. Median overall
survival of the entire population was 33.6 months (in-
terquartile range [IQR] 11–92.7 months). Patients under-
going classic surgery had a median overall survival of 40.3
months (IQR 14.9–96.6 months). The 3-year survival rates
of the three patient groups were 53% in the classic, 47%
in the combined and 58% in the reverse group. The lowest
rate of 180-day mortality (9%) was after the classic surgi-
cal approach. On a multivariate Cox proportional hazards
regression analysis, patient age >60 years (hazard ratio
[HR] 2.1, 95% confidence interval [CI] 1.1–3.9; p = 0.018),
R2-status (HR 2.08, 95% CI 1.03–4.2; p = 0.040), and >4
liver metastases (HR 2.4, 95% CI 1.2–4.6; p = 0.011) were
associated significantly with worse overall survival.
CONCLUSIONS: In patients undergoing surgical resec-
tion for synchronous colorectal liver metastases, promis-
ing survival rates could be achieved, irrespective of the
chosen surgical strategy. The presence of five or more liv-
er metastases, patient age over 60 years and R2-status
were found to be adverse risk factors.
Key words: colorectal cancer, synchronous liver metas-
tases, liver surgery, strategy, perioperative chemothera-
py, survival
Introduction
Colorectal cancer is the third most common malignancy in
men and women [1]. The liver is the most common site
of haematogenous metastases. The last two decades have
seen dramatic improvements in liver surgery techniques,
and the limits of resectability have changed in recent years.
Surgery remains the only potentially curative treatment for
resectable liver metastases. According to the literature, 20
to 50% of patients with resected liver metastases will sur-
vive 5 years or longer [2–5], and complete resection of liv-
er metastases has become a standard of care. In younger
patients with healthy liver tissue, as much as 75% of the
liver can be safely resected [6]. Perioperative mortality
rates of less than 5% have been reported in high-volume
expert centres [7].
However, despite liver resection with curative intent, re-
currences are frequent and approximately half of them oc-
cur in the liver only [5]. Complementing liver surgery by
chemotherapy has become a widely accepted approach,
aiming to treat micrometastases and to improve outcome.
A randomised study by the European Organisation for Re-
search and Treatment of Cancer [8] demonstrated that pe-
rioperative administration of 5-fluorouracil (5FU)- and ox-
aliplatin-based chemotherapy improved progression-free
survival and showed a trend towards improved overall sur-
vival over surgery alone for patients with resectable liv-
er metastases [9]. The evidence for a benefit is less clear
for adjuvant chemotherapy after liver resection. Pooled
analyses suggest a benefit for 5FU-based regimens with
or without oxaliplatin [10, 11]. Other studies demonstrated
that some initially unresectable disease can be rendered re-
sectable by preoperative chemotherapy [12]. However, the
optimal chemotherapy regimen has not been defined yet.
Approximately 20% of newly diagnosed patients with col-
orectal cancer have synchronous liver metastases. The syn-
chronous presentation of liver metastases is associated
with a worse outcome [13]. The traditional (“classic”)
strategy for these patients has been resection of the primary
tumour followed by liver resection, in combination with
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chemotherapy. Another option is a combined approach
with simultaneous resection of both the primary tumour
and the liver metastases. The third option is the so called
“reverse” strategy, with resection of the liver metastases
first and then resection of the colorectal primary in a sec-
ond step [14]. The latter strategy seems to be specifically
attractive for patients with extensive colorectal liver metas-
tases, and most patients receive chemotherapy beforehand
in order to reduce the size of the liver metastases.
Our multidisciplinary team has routinely incorporated
chemotherapy into the treatment plan for patients with
synchronous liver metastases. Furthermore, while tailoring
treatment to the specific needs of the patients, in recent
years we have been considering all three surgical strate-
gies. Treatment options were discussed at an interdiscipli-
nary tumour board, and for individual recommendations
both the presence or absence of symptoms and the extent
of the disease were considered. Formal guidelines on
which treatment strategy to choose did not exist.
The aim of this analysis was to review the treatment
modalities implemented in a multidisciplinary setting in a
tertiary academic referral centre, to report mortality after
extended periods of 90 and 180 days after surgery, includ-
ing the causes of death, and to report the disease-free and
overall survival of the patients.
Methods
Data collection
We performed a retrospective analysis based on a prospec-
tively collected database. Eligible patients for this analysis
had newly diagnosed colorectal cancer with synchronous
colorectal liver metastases, and were treated between May
2000 and October 2010 at the University Hospital Zurich.
Patients who had undergone resection of their primary tu-
mour at another institution were also eligible if the subse-
quent liver surgery was performed at our hospital. How-
ever, patients with incidental intraoperative discovery of
synchronous liver metastases were excluded, as the pres-
ence of liver metastases was not known when the inter-
disciplinary therapeutic strategy was defined. Data not yet
recorded in the prospective database were extracted from
the electronic patient charts. We assessed the treatment
strategy chosen, the type of chemotherapy regimen, includ-
ing the use of the monoclonal antibodies cetuximab or be-
vacizumab (when applicable), the timing of the chemother-
apy and the type of resection, as well as postoperative fatal
complications and mortality rates at 90 and 180 days af-
ter surgery. The main endpoint was overall survival, cal-
culated from the time of final resection to death or to
last follow-up. Patient follow-up was obtained from med-
ical records, letters or telephone contacts. This analysis
was approved by the local ethical committee (KEK-ZH-Nr.
2015-0055).
Treatment strategies
Our non-codified policy was, and still is, to resect colorec-
tal liver metastases either upfront shortly after resection of
the primary tumour, or after 2 to 3 months of preoperative
chemotherapy – often including monoclonal antibodies –
in patients with a high tumour burden considered initial-
ly nonresectable. Radiological assessments including fluo-
rodeoxyglucose-positron emission tomography / computed
tomography (FDG-PET/CT) and liver magnetic resonance
imaging are performed at baseline and then every 2 to 3
months during active treatment, and approximately every 6
months during follow-up.
All patients were discussed (sometimes repeatedly) at our
weekly multidisciplinary tumour board of expert liver sur-
geons, medical oncologists, radiation oncologists, gas-
troenterologists, radiologists and pathologists aiming for
a consensual therapeutic recommendation. The main deci-
sion factors were the extent and location of the primary tu-
mour, the preservation of sphincter function in the case of
rectal primaries, the extent of the hepatic tumour load and,
when patients had undergone neoadjuvant chemotherapy,
the response and the amount of residual disease.
The surgical treatment strategies in patients with synchro-
nous disease were defined as “classic” (resection of the pri-
mary followed by liver resection at a second operation),
“combined” (combining colorectal and planned liver re-
section in a single operation) and “reverse” (first liver re-
section followed by resection of the colorectal primary at
a second operation). In cases of complete radiological tu-
mour regression after chemotherapy, the original volume
of the liver parenchyma involved was resected. Depending
on the tumour burden in the liver, either a one-step or a
two-step liver resection was performed. A two-step ap-
proach consisted of a first surgery aiming at resection of
only parts of the liver metastases and in most cases an ad-
ditional ligation of the alternate side portal vein in order to
induce hypertrophy to the remnant liver. The second liv-
er surgery was then performed a few weeks later after ad-
equate parenchymal hypertrophy had occurred. The mod-
ern approach of associating liver partition and portal vein
ligation for staged hepatectomy (ALPPS procedure) was
not yet available at the cut-off date. Patients undergoing
ALPPS are not included in this analysis. Radiofrequency
ablation was used in a minority of patients in combination
with liver resection, when complete surgical resection was
not possible.
After liver surgery, the margins were determined through
serial sectioning by a pathologist. A positive margin was
defined as the finding of microscopic (R1) or gross (R2)
disease at the inked liver resection margin. Patients who
were assigned to a two-step procedure for their liver dis-
ease but did not proceed to the second step were also con-
sidered R2-resected.
Statistical analysis
We expressed the distribution of variables using means and
standard deviation [15] for normally distributed data, and
medians and interquartile ranges (IQRs) for non-normally
distributed data.
We compared the primary endpoint (overall survival) be-
tween the three groups (classic vs combined vs reverse
procedure) using univariate and multivariate Cox propor-
tional hazards regression models that take into account
time to event and censoring at either occurrence of event
(death), loss to follow-up or end of follow-up, with results
presented as hazard ratios (HRs) with 95% confidence in-
tervals (CIs). Confounding factors included in the mul-
tivariate model were chosen a priori based on clinical
interest and scientific knowledge. Based on this, the multi-
variate model was adjusted for possible confounders such
as age, R-status (R1/R2), nodal-status (positive/negative),
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preoperative chemotherapy (yes/no), postoperative
chemotherapy (yes/no) and number of lesions in the liver
(≤4/>4). Kaplan-Meier survival curves were used to pre-
sent disease-free and overall survival. The survival curves
were also stratified according to R-status and administra-
tion of chemotherapy. A p-value ≤0.05 was considered
statistically significant. All statistical analyses were per-
formed using STATA software (version 13, Stata Corp.,
College Station, Texas).
Results
Patient and treatment characteristics
During the study period, May 2000 to October 2010, 109
patients undergoing liver resection for synchronous col-
orectal metastases were identified. Patient and treatment
characteristic are summarised in table 1. The median age
of the patients was 58 years. Over half of the patients (59,
54%) had >4 liver lesions and 19 patients (17%) presented
with extrahepatic disease, mostly in the lungs and/or peri-
toneum.
In 82 patients the primary tumour was resected first, 20 had
a combined resection of both primary and liver metastases,
and 7 patients underwent liver resection followed by resec-
tion of the primary tumour (reverse strategy). The majori-
ty of patients having a classic or combined strategy had a
colon tumour (77% and 75%, respectively); most patients
in the reverse group presented with a rectal primary (71%).
A greater proportion of the patients with bilobar hepatic
disease (71%) underwent the reverse strategy as compared
with the other groups (classic 62%, synchronous 55%).
Of the 109 patients, 99 (92%) received chemotherapy, ei-
ther before surgery, between two surgical steps, and/or af-
ter surgery. Sixty-eight patients (83%) in the classic strat-
egy group received preoperative chemotherapy, compared
with only 6 (30%) in the combined and 5 (71%) in the re-
verse group. Monoclonal antibodies (bevacizumab or ce-
tuximab) were administered preoperatively to 38 patients
(46%) in the classic strategy group, 4 patients (20%) in the
combined and 4 patients (57%) in the reverse group. Three
patients from the classic strategy group received an antian-
giogenic tyrosine kinase inhibitor within a clinical study
protocol (table 1).
Intraoperative characteristics and histological results of all
three strategies are summarised in table 2. Macroscopically
complete resection was achieved in 68 (83%), 18 (90%)
and 7 (100%) patients, respectively, in the classic, com-
bined and reverse strategy groups. A one-step liver surgery
was performed in 55 patients (67%) in the classic strategy
as compared with 14 patients (70%) and 6 patients (86%)
in the combined and reverse groups.
Mortality after surgery
The overall 90-day mortality rate was 7%, 3 out of 82
(4%), 3 out of 20 (15%) and 1 out of 7 (14%), in the clas-
sic, combined and the reverse strategy groups, respective-
ly. Overall mortality rates after 180 days was 9%, 25% and
Table 1: Patient demographics.
All patients
n = 109
Classic strategy
n = 82
Combined strategy
n = 20
Reverse strategy
n = 7
Median age, years (interquartile range) 58.4
(51.8–66.6)
58.3
(51.8–66.0)
58.6
(52.3–72.7)
54.5
(47.9–66.7)
Sex, female/male, n (%) 37/72
(34/66%)
28/54
(34/66%)
7/13
(35/65%)
2/5
(29/71%)
Primary tumour, n (%)
Colon 80 (73%) 63 (77%) 15 (75%) 2 (29%)
Rectum 29 (27%) 19 (23%) 5 (25%) 5 (71%)
Extrahepatic disease, n (%) 19 (17%) 15 (18%) 2 (10%) 2 (29%)
Lung 12 (11%) 8 (10%) 2 (10%) 2 (29%)
Peritoneum 4 (4%) 4 (5%) 0 0
Other 3 (3%) 3 (4%) 0 0
Number of initial hepatic lesions, n (%)
≤ 4 lesions 50 (46%) 37 (45%) 11 (55%) 2 (29%)
> 4 lesions 59 (54%) 45 (55%) 9 (45%) 5 (71%)
Bilobar CRLM, n (%) 67 (62%) 51 (62%) 11 (55%) 5 (71%)
Preoperative chemotherapy, n (%) 79 (73%) 68 (83%) 6 (30%) 5 (71%)
Folfiri-based 20 (18%) 19 (23%) 1 (5%) 0
Folfox-based 45 (41%) 39 (48%) 3 (15%) 3 (43%)
5FU or capecitabine 3 (3%) 2 (2%) 0 1 (14%)
Floxuridine 2 (2%) 2 (2%) 0 0
Folfoxiri 2 (2%) 2 (2%) 0 0
Sequential Folfox- and Folfiri-based 7 (6%) 4 (5%) 2 (10%) 1 (14%)
Folfiri-based 20 (18%) 19 (23%) 1 (5%) 0
Preoperative monoclonal antibodies, n (%)
None 30 (28%) 26 (32%) 2 (10%) 1 (14%)
Cetuximab 5 (5%) 3 (4%) 0 2 (29%)
Bevacizumab 38 (35%) 33 (40%) 3 (15%) 2 (29%)
Cetuximab and bevacizumab 3 (3%) 2 (2%) 1 (5%) 0
VEGF-TKI* 3 (3%) 3 (4%) 0 0
Missing data 30 (28%) 15 (18%) 14 (70%) 2 (29%)
5FU = 5-fluorouracil; CRLM = colorectal liver metastases; VEGF-TKI = vascular endothelial growth factor-tyrosine kinase inhibitor * Antiangiogenetic tyrosine kinase inhibitor or
placebo within study protocol
Original article Swiss Med Wkly. 2017;147:w14486
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 7
29% (table 3). Notably, four of these patients developed fa-
tal tumour progression within 180 days. The main causes
for cumulative mortality up to 180 days after surgery were
pulmonary failure (four patients), sepsis (two patients),
small for size liver (two patients), and peritonitis and sui-
cide (one patient each).
Survival
The median observation time from the time of liver resec-
tion was 24.3 months (IQR 11.5–46.2 months). The medi-
an overall survival of the entire population, including the
patients who did not complete the planned resection strat-
egy, was 33.6 months (IQR 11–92.7 months). In the clas-
sic resection group, the median overall survival was 40.3
months (IQR 14.9–96.6 months), in the combined resec-
tion group 12.5 months (IQR 4.5–61.4 months), and was
not reached for the reverse strategy group (fig. 1). The
3-year survival rates of the three patient groups were 53%,
47% and 58%, respectively. The Cox proportional mod-
el for the combined vs the classic strategy showed a haz-
ard ratio of 2.6 (95% CI 1.2–5.7; p = 0.021) in favour of
the classic strategy. Reverse vs combined strategy revealed
a hazard ratio of 0.2 (95% CI 0.04–0.98; p = 0.047) in
favour of the reverse approach. The corresponding hazard
ratio for the reverse vs the classic strategy was 0.6 (95% CI
0.2–2.1; p = 0.433). The median disease-free survival was
7.2 months (IQR 3–19.7 months) for all patients. The me-
dian disease free survival was 7.7 months (IQR 3.3–19.6
months) in the classic resection group, 7.4 months (IQR
2.3–20.7 months) in the combined resection group, and 3.3
months (IQR 2.5–6 months) for the reverse strategy group
(fig. 2). No statistically significant difference was seen be-
tween the three groups: combined vs classic: HR 1.5, 95%
CI 0.7-2.9; p = 0.297; reverse vs classic HR 2.0, 95% CI
Table 3: Mortality rates after surgery.
90-day mortality 180-day mortality
Classic 4% (3 out of 83) 9% (7 out of 82)
Combined 15% (3 out of 20) 25% (5 out of 20)
Reverse 14% (1 out of 7) 29% (2 out of 7)
0.9–4.5; p = 0.110; and combined vs reverse HR 0.8, 95%
CI 0.2–3.1; p = 0.768.
Influence of perioperative chemotherapy
The use of any form of perioperative chemotherapy – pre-
operative, interval and/or postoperative – did not show any
statistically significant influence when compared with the
few patients (n = 10, 8%) not receiving any periopera-
tive chemotherapy. The median overall survival was 31.5
months (IQR 2.1 months – not reached) without and 40.2
months (IQR 11.8–92.7 months) with chemotherapy (HR
1.2, 95% CI 0.4–3.9; p = 0.785) (fig. 3).
Predictive factors
In a multivariate Cox proportional hazards regression
analysis, patient age >60 years (HR 2.1, 95% CI 1.1–3.9;
Figure 1: Overall survival according to treatment strategy. The
classic approach refers to resection of the primary tumour first fol-
lowed by liver surgery. The combined approach refers to simulta-
neous resection of the primary tumour and liver metastases. The
reverse approach refers to resection of liver metastases before re-
section of the primary tumour. In the classic resection group, medi-
an overall survival was 40.3 months (IQR 14.9–96.6 months), in
the combined resection group 12.5 months (IQR 4.5–61.4
months), and was not reached for the reverse strategy group.
Classic vs combined strategy: HR 2.6 (95% CI 1.2–5.7; p = 0.021);
classic vs reverse strategy: HR 0.6 (95% CI 0.2–2.1; p = 0.433);
combined vs reverse strategy: HR 0.2 (95% CI 0.04–0.98; p =
0.047).
Table 2: Intraoperative parameters and histological results.
All patients
n = 109
Classic strategy
n = 82
Combined strategy
n = 20
Reverse strategy
n = 7
Nodal status positive, n (%) 77 (71%) 56 (68%) 15 (75%) 6 (86%)
R-status of liver resection, n (%)
R0 61 (56%) 46 (56%) 11 (55%) 4 (57%)
R1 32 (29%) 22 (27%) 7 (35%) 3 (43%)
R2 16 (15%) 14 (17%) 2 (10%) 0%
Liver resection, n (%)
One step 75 (69%) 55 (67%) 14 (70%) 6 (86%)
Two step 24 (22%) 17 (21%) 6 (30%) 1 (14%)
Relapse resection 1 (1%) 1 (1%) 0 0
Failed two step 9 (8%) 9 (11%) 0 0
Portal vein ligation, n (%) 22 (20%) 19 (23%) 3 (15%) 0
Type of liver resection, n (%)
Hemihepatectomy incl. extended 63 (58%) 49 (60%) 10 (50%) 4 (57%)
Typical wedge 45 (41%) 32 (39%) 10 (50%) 3 (43%)
Atypical wedge 1 (1%) 1 (1%) 0 0
Additional surgery, n (%)
Extrahepatic metastasectomy 3 (4%) 3 (5%) 0 0
Ablation 9 (8%) 7 (9%) 1 (5%) 1 (14%)
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p = 0.018), R2-status (HR 2.08, 95% CI 1.03–4.2; p =
0.040), and presence of more than four liver metastases
(HR 2.4, 95% CI 1.2–4.6; p = 0.011) were associated with
a significantly worse overall survival.
Median overall survival in patients with R0 resection was
52.7 months (IQR 8.9 months – not reached), whereas sur-
vival for those patients with R1 resection was 20.5 months
(IQR 6.3 months – not reached; R1 vs R0 HR 9.4, 95% CI
1.1–79.2; p = 0.040) and for patients with R2 resection sta-
tus was 10.7 months (IQR 5.9 months – not reached; R2 vs
R0 HR 8.6, 95% CI 0.9–79.2; p = 0.057). The correspond-
ing hazard ratio for R1 vs R2 was 0.95 (95% CI 0.4-2.4; p
= 0.92) (fig. 4).
Discussion
This study reports the outcome of patients with synchro-
nous liver metastases of colorectal cancer treated by a mul-
tidisciplinary team at a Swiss tertiary referral centre. Most
patients underwent classic surgery, with resection of the
primary first. The best survival rates were observed in pa-
tients whose disease burden allowed for a complete resec-
tion (R0-resection).
Determining the best strategy for patients with synchro-
nous liver metastases is challenging because a number of
Figure 2: Disease-free survival according to treatment strate-
gy. The median disease-free survival was 7.7 months (IQR
3.3–19.6 months) in the classic surgery group, 7.4 months in the
combined resection group (IQR 2.3–20.7 months), and for the re-
verse strategy group 3.3 months (IQR 2.5–6 months). Combined
vs classic strategy: HR 1.5 (95% CI 0.7–2.9; p = 0.297); reverse vs
classic strategy: HR 2.0 (95% CI 0.9–4.5; p = 0.110); combined vs
reverse strategy: HR 0.8 (95% CI 0.2–3.1; p = 0.768).
Figure 3: Impact of perioperative chemotherapy on overall
survival. Median overall survival was 31.5 months (IQR 2.1
months – not reached) without chemotherapy vs 40.2 months (IQR
11.8–92.7 months) with any chemotherapy.
factors need to be taken into account. The reverse approach
has expanded our treatment options for patients with syn-
chronous liver metastases from colorectal primaries in re-
cent years. During the observed decade, only a minority
(20 out of 109 patients) were treated according to a com-
bined strategy, and an even smaller number (7 out of 109
patients) according to a reverse treatment approach. Pa-
tients treated according to the reverse strategy had predom-
inantly rectal primaries, advanced (more than four lesions)
and/or bilobar liver disease.
The median overall survival was 34 months for all patients,
including the patients who did not complete their planned
two-step resection. The longest survival was seen in pa-
tients in the classic strategy group, with a median of 40
months. The relative risk of death was more than doubled
in the combined compared with the classic strategy group
(HR 2.6, 1.2–5.7; p = 0.021). This discrepancy is surpris-
ing, since fewer patients in the combined group had ad-
vanced/bilobar disease and extrahepatic spread, compared
with the patients assigned to the classic approach. This dif-
ference in outcome may be in part due to the higher 90-day
mortality rate in the combined patient group (15% vs 4%),
though patient numbers were too small to perform mean-
ingful statistical comparisons. However, if the estimated
3-year overall survival is taken into account, the results
were rather similar in all three groups, at about 50%, high-
lighting the potential to achieve long-term survival with
different surgical techniques.
Our survival results are in line with other reports, consid-
ering that the majority of the patients had extensive dis-
ease with five or more liver metastases, and more than
60% of the patients had bilobar disease [16–18]. In addi-
tion, almost 20% of our patients had extrahepatic tumour
spread. The presence of synchronous liver metastases and
extrahepatic spread are established adverse prognostic fac-
tors per se. However, this cohort of more than 100 patients
represents real-world experience and the large proportion
of patients with adverse risk factors may have contributed
substantially to the outcome. As in other reports, our series
suggests that aggressive treatment, incorporating
chemotherapy and extended surgery, may improve out-
Figure 4: Overall survival according to resection status. Medi-
an overall survival in patients with R0 resection was 52.7 months
(IQR 8.9 months – not reached), whereas survival for those pa-
tients with R1 resection was 20.5 months (IQR 6.3 months – not
reached), and for patients with R2 resection status 10.7 months
(IQR 5.9 months – not reached). R0 is associated with improved
survival; R1 vs R0: HR 9.4 (95% CI 1.1–79.2; p = 0.040); R2 vs
R0: HR 8.6 (95% CI 0.9–79.2; p = 0.057); R1 vs R2: HR 0.95 (95%
CI 0.4–2.4; p = 0.92).
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come in selected patients even with extensive tumour bur-
den [19, 20].
Earlier studies have suggested different prognostic factors
in order to improve patient selection for aggressive surgery
[21–23]. Size and number of liver metastases, among oth-
ers, were described as negative prognostic factors, al-
though no consensus about the appropriate cut-offs was
reached. Fong et al. developed a score [24], which includes
number and size of liver metastases, preoperative carci-
noembryonic antigen levels and lymph node positivity as
independent risk factors. In our study, negative margins
(R0) were associated with superior survival (53 months vs
20.5 months for R1 and 11 months for R2). Furthermore,
we found that age >60 and more than 4 tumour lesions in
the liver were significantly associated with a worse over-
all survival. Main reasons for early mortality were tumour
progression, pulmonary failure and sepsis. Liver-related
fatal perioperative complications occurred rarely (small for
size liver, two patients).
For our patients following a classic strategy, chemotherapy
was routinely administered between resection of the pri-
mary and liver resection. In patients undergoing combined
resection, perioperative chemotherapy was commonly ad-
ministered. In patients for whom the reverse strategy was
chosen, chemotherapy was administered before liver re-
section in the majority of cases. A delay of chemotherapy
in this particular population, allowing tumour progression,
would probably preclude curative surgery. However, we
found that chemotherapy administration, with or without
monoclonal antibodies, showed a trend but did not sig-
nificantly improve survival independently of the chosen
strategy, compared with the patients who did not receive
chemotherapy before or after liver surgery. This result is
not surprising, as most patients had received some form
of systemic treatment, and patient numbers in this analysis
were too small to draw meaningful conclusions. However,
a prospective randomised controlled trial and a few pooled
analyses of available data suggest that perioperative or ad-
juvant chemotherapy may contribute to improved outcome
[10, 11, 25].
This was a retrospective analysis at a single institution, and
selection bias and other unknown confounders may be in-
herent. To control for confounding effects, we adjusted the
results for possible, assesse, and known confounders by us-
ing multivariable regression analysis. Since we are a ter-
tiary referral centre, some of the primary treatment deci-
sions had been made at other institutions. Small patient
numbers limit the statistical power to draw specific con-
clusions. Additionally, the comparison between strategies
is formally difficult in a retrospective analysis because the
choice strategy depends mainly on the extent of the dis-
ease; thus, differences in outcome may simply reflect the
differences of the tumour burden between the groups. This
assumption is supported by the rather short disease-free
survival in patients undergoing reverse surgery as com-
pared with the other two approaches, although numbers
were too small to demonstrate statistically significant dif-
ferences. Patient heterogeneity may be also an explanation
for the higher mortality rates seen in the reverse and com-
bined surgery groups compared with the classic surgery
group. As every centre may apply different selection cri-
teria for surgical treatment, the reported patient outcome
may thus differ between institutions. Lastly, we cannot
provide comprehensive data on second-line treatment,
since this information was not systematically recorded.
However, we assume that best available therapy was pro-
vided according to the treating physician.
In only a minority of patients with liver metastases of col-
orectal cancer can the metastases be completely resected.
Innovative surgical and interventional techniques, such as
portal vein embolisation or ligation, staged hepatectomy
and radio frequency ablation, have been developed in re-
cent years [6, 26, 27]. Recently, the ALPPS procedure has
been introduced and shown promising results, especially in
patients with extensive bilobar disease [28, 29]. Addition-
ally, several reports have shown the potential of preoper-
ative chemotherapy to successfully downsize the disease
and thereby improve resectability [30, 31]. Our group has
employed broadly both perioperative chemotherapy and an
aggressive surgical strategy. Our data show that long-term
survival can be achieved, specifically for patients with
completely resection, with a median overall survival of 53
months. Unfortunately, most patients experience intra- or
extrahepatic disease recurrence [32] regardless of the treat-
ment strategy. This emphasises the need to develop more
effective anticancer drugs and to carefully select patients
for a particular surgical strategy.
Conclusion
In selected patients undergoing surgical resection for syn-
chronous colorectal liver metastases, promising survival
rates could be achieved, irrespective of the chosen surgical
strategy. The treatment strategy depended on various fac-
tors, mainly the extent of liver disease, and was chosen for
each individual patient by a multidisciplinary team. The
presence of five or more liver metastases, patient age over
60 years, and R2-status were found to be adverse risk fac-
tors, whereas complete (microscopic) tumour resection is
crucial for improved survival.
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